福建一IVD公司被建设银行起诉！

IVD新品位02-15

请求“星标”，否则收不到推送，谢谢来源：企查查、体外诊断网近日，企查查公开信息披露，2026年1月以来，福建阿吉安生物科技有限公司（下称“阿吉安生物”）密集出现被执行、股权司法冻结、金融借款纠纷被银行起诉等多项重大经营风险，公司实控人同步被限制高消费，旗下多家全资子公司亦被列入被执行人名单，经营状况逐渐恶化。据公开信息显示，2026年1月8日，阿吉安生物被福建省福州市闽侯县人民法院列为被执行人，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2611122644?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-15 20:31","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2611122644","market":"hk","top_or_hot":-1,"title":"福建一IVD公司被建设银行起诉！","media":"IVD新品位","content":"<div>\n<p>请求“星标”，否则收不到推送，谢谢来源：企查查、体外诊断网近日，企查查公开信息披露，2026年1月以来，福建阿吉安生物科技有限公司（下称“阿吉安生物”）密集出现被执行、股权司法冻结、金融借款纠纷被银行起诉等多项重大经营风险，公司实控人同步被限制高消费，旗下多家全资子公司亦被列入被执行人名单，经营状况逐渐恶化。据公开信息显示，2026年1月8日，阿吉安生物被福建省福州市闽侯县人民法院列为被执行人，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021521192197a64629&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>福建一IVD公司被建设银行起诉！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n福建一IVD公司被建设银行起诉！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-15 20:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021521192197a64629&s=b><strong>IVD新品位</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>请求“星标”，否则收不到推送，谢谢来源：企查查、体外诊断网近日，企查查公开信息披露，2026年1月以来，福建阿吉安生物科技有限公司（下称“阿吉安生物”）密集出现被执行、股权司法冻结、金融借款纠纷被银行起诉等多项重大经营风险，公司实控人同步被限制高消费，旗下多家全资子公司亦被列入被执行人名单，经营状况逐渐恶化。据公开信息显示，2026年1月8日，阿吉安生物被福建省福州市闽侯县人民法院列为被执行人，...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021521192197a64629&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1961090484.USD","symbol_name":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021521192197a64629&s=b","article_id":"2611122644","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021521192197a64629&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2611122644","pubTimestamp":1771158665,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"据公开信息显示，2026年1月8日，阿吉安生物被福建省福州市闽侯县人民法院列为被执行人，执行标的达43764元，被标注为高风险事项。2月5日，福州市台江区人民法院新增立案，中国建设银行股份有限公司福州五一支行因金融借款合同纠纷，正式起诉阿吉安生物。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1961090484.USD":"ALLIANZ ALL CHINA EQUITY \"A\" (USD) INC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU1211504680.USD":"ALLIANZ HIGH DIVIDEND ASIA PACIFIC EQUITY \"AM\" (USD) INC","LU0871576103.HKD":"HSBC GIF CHINESE EQUITY \"AC\" (HKD) ACC","LU0531971595.HKD":"HSBC GIF CHINESE EQUITY \"AD\" (HKD) INC","LU0791591158.USD":"ALLSPRING  EMERGING MARKTES EQUITY INCOME \"I\" (USD) ACC","LU1568876335.HKD":"ALLIANZ CHINA MULTI INCOME PLUS \"AMG\" (HKD) INC","LU0918141887.USD":"安联亚洲实际收益股票基金","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2087589342.USD":"BGF ASIAN MULTI-ASSET INCOME \"A6\" (USD) INC","LU0431992006.USD":"摩根大通新兴市场机会A（acc）","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","LU0630378429.USD":"HSBC GIF ASIA PACIFIC EX JAPAN EQ HD \"AM2\" (USD) INC","LU1048484197.HKD":"ALLIANZ CHINA MULTI INCOME PLUS \"AT\" (HKD) ACC","IE00BVYPNQ40.USD":"GUINNESS ASIAN EQUITY INCOME \"C\" (USD) ACC","LU1044875133.USD":"天利亚洲反向股票 AU Acc","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU0675040207.SGD":"JPM ASIA PACIFIC EQUITY \"A\" (SGD) ACC","00939":"建设银行","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0396098781.USD":"ALLIANZ CHINA MULTI INCOME PLUS \"AT\" (USD) ACC","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","03143":"华夏香港银行股","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0163747925.USD":"EASTSPRING INVESTMENTS ASIAN EQUITY A ACC","LU1323998911.USD":"BGF ASIAN MULTI-ASSET INCOME \"A\" (USD) ACC","IE00BPRC5H50.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0293314216.USD":"ALLIANZ GEM EQUITY HIGH DIVIDEND \"A\" (USD) ACC","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","IE0003895053.USD":"PINEBRIDGE ASIA DYNAMIC ASSET ALLOCATION \"AD\" USD  ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1770034418.SGD":"ALL CHINA EQUITY \"A\" (SGDHDG) ACC","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU1224709979.USD":"FIDELITY CHINA FOCUS \"A\" (USD) ACC","IE00BYV24P56.USD":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (USD) ACC","LU1770036033.HKD":"NINETY ONE GSF ASIAN EQUITY \"A\" (HKD) ACC","LU0540923850.HKD":"ALLIANZ HONG KONG EQUITY \"A\" (HKD) INC","LU1880383440.USD":"AMUNDI FUNDS CHINA EQUITY \"A2\" (USD) INC","IE00BMCWC346.EUR":"GUINNESS EMERGING MARKETS EQUITY INCOME \"C\" (EUR) ACC","IE00B3M56506.USD":"NEUBERGER BERMAN EMERGING MARKETS EQUITY \"A\" (USD) ACC","LU0797268264.HKD":"ALLIANZ TOTAL RETURN ASIAN EQUITY \"AT\" (HKD) ACC","LU0348805143.USD":"ALLIANZ ENHANCED ALL CHINA EQUITY \"A\" (USD) INC","LU0633140727.USD":"AB EMERGING MARKETS MULTI ASSET PORTFOLIO \"AD\" (USD) INC"},"translate_title":"An IVD company in Fujian was sued by China Construction Bank!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00939":1.5,"03143":0.6},"content_text":"请求“星标”，否则收不到推送，谢谢来源：企查查、体外诊断网近日，企查查公开信息披露，2026年1月以来，福建阿吉安生物科技有限公司（下称“阿吉安生物”）密集出现被执行、股权司法冻结、金融借款纠纷被银行起诉等多项重大经营风险，公司实控人同步被限制高消费，旗下多家全资子公司亦被列入被执行人名单，经营状况逐渐恶化。据公开信息显示，2026年1月8日，阿吉安生物被福建省福州市闽侯县人民法院列为被执行人，执行标的达43764元，被标注为高风险事项。仅十余日后，公司资产层面再受重创。1月17日、1月30日，阿吉安生物持有的福州奥吉芯生物科技有限公司股权，连续两次被司法冻结，冻结股权数额为4.38万元，冻结期限自2026年1月8日至2027年1月7日，该事项被平台标记为中风险，意味着公司对外投资资产已被司法管控，资金与资产流动性进一步受限。2月，阿吉安生物的债务纠纷升级至诉讼阶段。2月5日，福州市台江区人民法院新增立案，中国建设银行股份有限公司福州五一支行因金融借款合同纠纷，正式起诉阿吉安生物。法院同步公告，该案将于2026年3月11日开庭审理，意味着公司与银行的借贷违约问题已进入司法审理程序，面临偿付、罚息等法律责任，现金流压力进一步凸显。从企业主体结构来看，阿吉安生物大股东为福州奥吉吉投资合伙企业（有限合伙），持股比例达45.1344%，且该股东已出现股权出质状况；公司法定代表人、董事长、经理史保明，同时为公司实际控制人、受益所有人，目前已被司法机关限制高消费。风险亦传导至其旗下全资及参股企业。企查查对外投资信息显示，阿吉安生物对外投资5家企业。其中，福州吉昂医学检验实验室有限公司、福州奥吉芯生物科技有限公司两家全资子公司，均被列为被执行人，福州奥吉芯生物同时被限制高消费，进一步折射出阿吉安生物整体板块的经营失序与管控失效。短时间内，从被执行、股权冻结，到银行起诉、实控人限高，再到子公司同步暴险，阿吉安生物接连爆发的系列风险，直指公司资金链紧张、债务违约、经营管理失范等核心问题。随着金融借款纠纷案开庭临近，公司后续偿付能力、资产处置及经营走向，仍待进一步观察。关于阿吉安公开资料显示，阿吉安生物是一家掌握多项全球前沿、全国领先核心技术的创新型生物医学高新技术企业。公司成立于2017年，作为中国最早深耕病原感染诊断的企业之一，致力于高灵敏基因检测技术在医学领域的研发和应用。公司以mNGS、PCR等分子诊断技术平台，为临床提供病原微生物检测、PCR检测、新冠病毒核酸检测等感染性疾病精准诊疗解决方案。同时开展分子诊断试剂、设备的研发和生产制造业务，共同满足临床对感染性疾病诊疗以及时效性需求，为广大客户提供疾病综合诊疗方案。声明：本文仅代表作者观点，不代表平台立场，如果转载涉及版权等问题，请尽快联系我们，我们第一时间更正或删除，谢谢！","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2611122644","isCrawlerRequest":true}